Title: Role of Intravitreal Bevacizumab for the Treatment of Acute Central Serous Chorioretinopathy
Authors: Parvez Ahmad Bhat, Arsalan Un Nisa, Shiraz Ahmad Bhat
DOI: https://dx.doi.org/10.18535/jmscr/v8i7.40
Abstract
Purpose: To find out the role of intravitreal bevacizumab in the treatment of acute central serous chorioretinopathy (CSC).
Methods: A total of 24 patients of CSC were included in this study and were divided into two groups with 12 patients each. Treatment group received a single intravitreal injection of bevacizumab (1.25mg/0.05ml; Avastin) and in other group no treatment was given and served as control group. Central maculat thickness (CMT) and best corrected visual acuity (BCVA) were measured at baseline, 6 weeks,10 weeks,18 weeks and 24 weeks and were compared between treatment and control groups.
Results: Mean CMT in treatment group at baseline was 507.92±81.37µ (range: 380-630µ) which improved to 392.17±65.63µ (p value-0.000) at 6 weeks; 344.67±59.93µ (p value-0.000) at 12 weeks; 296.83±39.93µ (p value-0.000) at 18 weeks and 269.75±30.85µ (p value-0.000) at 24 weeks after injection. Baseline BCVA in treatment group was 0.58 log MAR units which improved to 0.44 log MAR (p value-0.000) at 6 weeks; 0.33 log MAR (p value-0.000) at 12 weeks; 0.26 log MAR (p value-0.000) at 18 weeks and 0.12 log MAR (p value-0.000) at 24 weeks after injection. Mean CMT in control group at baseline was 505.92±123.78µ (Range: 310-670µ) which improved to 398.67±79.23µ (p value-0.000) at 6 weeks; 360.42±73.37µ (p value-0.000) at 12 weeks; 324.67±56.36µ (p value-0.000) at 18 weeks and 293.83±83µ (p value-0.000) at 24 weeks after injection. Mean baseline BCVA in control group was 0.57 log MAR units which improved to 0.47 log MAR (p value-0.000) at 6 weeks; 0.37 log MAR (p value-0.000) at 12 weeks; 0.27 log MAR (p value-0.000) at 18 weeks and 0.175 log MAR (p value 0.000) at 24 weeks after injection. On comparison of CMT and BCVA at baseline and different follow-ups, between the two groups, no statistically significant difference was seen.
Conclusion: In this study we found that there was no benefit of intravitreal bevacizumab over observation in the management of acute CSC.
Keywords: central serous chorioretinopathy (CSC), best corrected visual acuity (BCVA), central macular thickness (CMT), photodynamic therapy (PDT), optical coherence tomography (OCT), fundus fluorescein angiography (FFA).
References
- Hayashi K, Hasegawa Y, Tokoro T: Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol 1986; 9: 37–41
- Stanga PE, Lim JI, Hamilton P: Indocyaninegreen angiography in chorioretinal diseases: indications and interpretation: an evidence based update. Ophthalmology 2003; 110: 15–21
- Menchini U, Virgili G, Lanzetta P, Ferrari E: Indocyanine green angiography in central serous chorioretinopathy. Int Ophthalmol .1997; 21: 57–69.
- Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D: Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994; 112: 1057–1062.
- Weis SM, Cheresh DA: Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437: 497–504.
- Niegel MF, Schrage NF, Christmann S, Degenring RF: Intravitreal bevacizumab for chronic central serous chorioretinopathy (in German). Ophthalmologe 2008; 105: 943–945.
- Wang MS, Sander B, Larsen M: Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 2002; 133: 787–793.
- Wang M, Sander B, la Cour M, Larsen M: Clinical characteristics of subretinal deposits in central serous chorioretinopathy. Acta Ophthalmol Scand 2005; 83: 691–696.
- Ober MD, Yannuzzi LA, Do DV, et al: Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005; 112: 2088–2094.
- Burumcek E, Mudun A, Karacorlu S, et al: Laser photocoagulation for persistent central serous retinopathy: results of long-term follow- up. Ophthalmology 1997; 104: 616 -622.
- Kanyange ML, De Laey JJ: Long-term follow- up of central serous chorioretinopathy (CSCR). Bull Soc Belge Ophtalmol 2002; 284: 39–44.
- Mennel S, Peter S, Meyer CH, et al: Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1015–1021.